bluebird bio (BLUE)
(Delayed Data from NSDQ)
$1.01 USD
+0.07 (7.13%)
Updated Aug 8, 2024 03:59 PM ET
After-Market: $0.99 -0.02 (-1.98%) 7:56 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
bluebird bio, Inc. [BLUE]
Reports for Purchase
Showing records 341 - 360 ( 533 total )
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
4Q/FY16, First Look at Improved LentiGlobin and Updates from bb2121 Program Expected in June, Reiterate OP
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
LentiGlobin Needs More Time in SCD; Downgrading to Neutral and $71 PT
Provider: Roth Capital Partners, Inc.
Analyst: BREIDENBACH M
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
LentiGlobin Needs More Time in SCD; Downgrading to Neutral and $71 PT
Provider: Roth Capital Partners, Inc.
Analyst: BREIDENBACH M
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
ASH Updates Reinforce LentiGlobin Clinical Profile, Dosing with More Potent Product Expected Shortly, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
ASH Readout Leaves Room for Optimism in SCA; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: BREIDENBACH M
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Anti-BCMA CAR-T Shows Potent Activity with Clean Safety, BLUE Well Positioned into 2017, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
First-In-Man bb2121 Results Do Not Disappoint; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: BREIDENBACH M
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
ASH 2016: Additional Abstracts and Sessions of Interest
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
BLUE to Present bb2121 BCMA-CAR-T Data at "Triple" Meeting
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
3Q, ASH Update Reinforces Our Outlook on LentiGlobin, but Doubts over Benefit Profile in SCD Remain Unresolved, Reiterate OP but Lowering PT to $95
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Looks Like a Mixed Bag at ASH, Reiterate Buy and $87 PT
Provider: Roth Capital Partners, Inc.
Analyst: BREIDENBACH M
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
R-D Day Highlights Improvements to Gene Therapy Platform, Favorable Regulatory Response, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Our Key Takeaways from R-D Day; Reiterate Buy and $87 PT
Provider: Roth Capital Partners, Inc.
Analyst: BREIDENBACH M
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences - Upcoming Events for the Week of Oct 10
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D